Reverse Phase Protein Microarray Technology: Advances into the Clinical Research Arena - Proteomic and Metabolomic Approaches to Biomarker Discovery - page 349

42. Humphery-Smith I, Wischerhoff E, Hashimoto R.
Protein arrays for assessment of target selectivity.
Drug Discovery World 2002;4:17 e 27.
43. Hunter T. Signaling e 2000 and beyond. Cell 2000;100:
113 e 27.
44. Hynes NE, Lane HA. ERBB receptors and cancer: the
complexity of targeted inhibitors. Nat Rev Cancer 2005;
5:341 e 54.
45. Iyengar P, Espina V, Williams TW, et al. Adipocyte-
derived collagen VI affects early mammary tumor
progression in vivo, demonstrating a critical interac-
tion in the tumor/stroma microenvironment. J Clin
Invest 2005;115:1163 e 76.
46. Jain KK. Personalized medicine. Curr Opin Mol Ther
2002;4:548 e 58.
47. Jiang R, Mircean C, Shmulevich I, et al. Pathway alter-
ations during glioma progression revealed by reverse
phase protein lysate arrays. Proteomics 2006;6:2964 e 71.
48. Jones RB, Gordus A, Krall JA, MacBeath G. A quan-
titative protein interaction network for the ErbB
receptors using protein microarrays. Nature 2006;439:
168 e 74.
49. King G, Payne S, Walker F, Murray GI. A highly
sensitive detection method for immunohistochemistry
using biotinylated tyramine. J Pathol 1997;183:237 e 41.
50. Korf U, Derdak S, Tresch A, et al. Quantitative protein
microarrays for time-resolved measurements of
protein phosphorylation. Proteomics 2008;8:4603 e 12.
51. Krishnamurty R, Maly DJ. Biochemical mechanisms of
resistance to small-molecule protein kinase inhibitors.
ACS Chem Biol 2010;5:121 e 38.
52. Kusnezow W, Syagailo YV, Ruffer S, et al. Optimal
design of microarray immunoassays to compensate
for kinetic limitations: theory and experiment. Mol Cell
Proteomics 2006;5:1681 e 96.
53. Li J, Gould TD, Yuan P, Manji HK, Chen G. Post-
mortem interval effects on the phosphorylation of
signaling proteins. Neuropsychopharmacology 2003;28:
1017 e 25.
54. Li X, Friedman AB, Roh MS, Jope RS. Anesthesia and
post-mortem interval profoundly in

59. Liotta LA, Petricoin III EF. -omics and cancer
biomarkers: link to the biological truth or bear the
consequences. Cancer Epidemiol Biomarkers Prev 2012;
21(8):1229 e 35.
60. Loebke C, Laible M, Rappl C, et al. Contact spotting of
protein microarrays coupled with spike-in of normal-
izer protein permits time-resolved analysis of ERBB
receptor signaling. Proteomics 2008;8:1586 e 94.
61. Loebke C, Sueltmann H, Schmidt C, et al. Infrared-
based protein detection arrays for quantitative pro-
teomics. Proteomics 2007;7:558 e 64.
62. Ma Y, Ding Z, Qian Y, et al. Predicting cancer drug
response by proteomic pro ling. Clin Cancer Res 2006;

12:4583 e 9.
63. Ma Y, Ding Z, Qian Y, et al. An integrative genomic
and proteomic approach to chemosensitivity predic-
tion. Int J Oncol 2009;34:107 e 15.
64. MacBeath G, Schreiber SL. Printing proteins as
microarrays for high-throughput function determina-
tion. Science 2000;289:1760 e 3.
65. Machida K, Thompson CM, Dierck K, et al. High-
throughput phosphotyrosine pro ling using SH2

domains. Mol Cell 2007;26:899 e 915.
66. Mammano E, Galdi F, Pierobon M, et al. Multiplexed
protein signal pathway mapping identi

es patients
with rectal cancer that responds to neoadjuvant
treatment, http://www.ncbi.nlm.nih.gov/pubmed/
22658458 ; 2012.
67. Mazzone M, Selfors LM, Albeck J, et al. Dose-
dependent induction of distinct phenotypic responses
to Notch pathway activation in mammary epithelial
cells. Proc Natl Acad Sci USA 2010;107:5012 e 7.
68. Medina PJ, Goodin S. Lapatinib: a dual inhibitor of
human epidermal growth factor receptor tyrosine
kinases. Clin Ther 2008;30:1426 e 47.
69. Mendoza M, Khanna C. Revisiting the seed and soil in
cancermetastasis. Int J BiochemCell Biol 2009;41:1452 e 62.
70. Mueller C, Zhou W, Vanmeter A, et al. The heme
degradation pathway is a promising serum biomarker
source for the early detection of Alzheimer ' s disease.

uence the regu-
latory serine phosphorylation of glycogen synthase
kinase-3 in mouse brain. J Neurochem 2005;92:701 e 4.
55. Liotta L, Petricoin E. Molecular pro

J Alzheimers Dis 2010;19:1081 e 91.
71. Mueller C, Liotta LA, Espina V. Reverse phase protein
microarrays advance to use in clinical trials. Mol Oncol
2010;4(6):461 e 81. Published online October 16, 2010.
72. Mueller C, Edmiston KH, Carpenter C, et al. One-step
preservation of phosphoproteins and tissue mor-
phology at room temperature for diagnostic and
research specimens. PLoS ONE 2011;6(8):e23780.
73. Nassiri M, Ramos S, Zohourian H, et al. Preservation
of biomolecules in breast cancer tissue by a formalin-
free histology system. BMC Clin Pathol 2008;8:1.
74. Nishizuka S, Charboneau L, Young L, et al. Proteomic
pro

ling of human

cancer. Nat Rev Genet 2000;1:48 e 56.
56. Liotta LA, Espina V, Mehta AI, et al. Protein micro-
arrays: meeting analytical challenges for clinical

applications. Cancer Cell 2003;3:317 e 25.
57. Liotta LA, Kohn EC. The microenvironment of the
tumour-host interface. Nature 2001;411:375 e 9.
58. Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics:
personalized molecular medicine.

JAMA 2001;286:

2211 e 4. ling of the NCI-60 cancer cell lines using new